Status:
TERMINATED
Utilization of MAsS in Patients Undergoing LT for HCC
Lead Sponsor:
Columbia University
Collaborating Sponsors:
Amra Medical AB
Conditions:
NAFLD
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.
Detailed Description
The combination of hepatocellular carcinoma and chronic liver disease represents a dual impact on overall metabolism. The major risk factors for chronic liver disease related-hepatocellular carcinoma ...
Eligibility Criteria
Inclusion
- Age between 18 and 75 years
- Diagnosis of cirrhosis and HCC
- Listed or in evaluation for liver transplantation
Exclusion
- History of prior solid organ transplantation
- In evaluation or listed for any other solid organ transplant (other than liver transplant)
- Contraindication to MR examination
- Metastatic HCC
Key Trial Info
Start Date :
June 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 29 2023
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT05184283
Start Date
June 16 2022
End Date
November 29 2023
Last Update
December 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center
New York, New York, United States, 10032